Medical University Innsbruck — Biomedical Watch V2

Traitements5programmes

Essais2liés

Publications10liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Primary major amputationThe primary objective of this study is to evaluate the effect of different treatment modalities on clinical outcome of patients suffering from acute lower limb ischemia (ALI). Depending on clinical presentation, anatomical as well as technical considerations, different treatment options are available for revascularisation of affected limbs. Using an observational, international, multicentric study design (min. patient number of 500), the defined primary endpoint of the study, amputation-free survival 90 days after the diagnosis of ALI, will be evaluated.	Myopathies	À vérifier	À vérifier	Austria, Croatia, France, Germany, Hungary, Moldova, Netherlands, Serbia, …	À vérifier
RevascularizationThe primary objective of this study is to evaluate the effect of different treatment modalities on clinical outcome of patients suffering from acute lower limb ischemia (ALI). Depending on clinical presentation, anatomical as well as technical considerations, different treatment options are available for revascularisation of affected limbs. Using an observational, international, multicentric study design (min. patient number of 500), the defined primary endpoint of the study, amputation-free survival 90 days after the diagnosis of ALI, will be evaluated.	Myopathies	À vérifier	À vérifier	Austria, Croatia, France, Germany, Hungary, Moldova, Netherlands, Serbia, …	À vérifier
Selective CRP apheresis using the PentraSorb®-CRP systemBackground: In patients with acute ST-elevation myocardial infarction (STEMI), the amount of infarcted myocardium (infarct size) is known to be a major predictor for adverse remodeling and recurrent adverse cardiovascular events. Effective cardio-protective strategies with the aim of reducing infarct size are therefore of great interest. Local and systemic inflammation influences the fate of ischemic myocardium and thus, adverse remodeling and clinical outcome. C-reactive protein (CRP) also acts as a potential mechanistic mediator that adversely affects the amount of irreversible myocardial tissue damage after acute myocardial infarction. Objective: The main objectives of the current study are to investigate the efficacy of selective CRP apheresis, using the PentraSorb®-CRP system, as an adjunctive therapy to standard of care for patients with acute STEMI treated with primary PCI. Design: Investigator-initiated, prospective, randomized, open-label (outcome assessors masked), controlled, multicenter, two group trial with a two-stage adaptive design. Innovation: Selective CRP apheresis offers potential to decrease infarct size and consequently improve outcome after PCI for STEMI. This is the first randomized trial investigating the impact of selective CRP apheresis on infarct size in post-STEMI patients. In perspective, the study design allows furthermore to collect robust evidence for the design of a definitive outcome study.	Maladie coronarienne	Non applicable	Immunomodulation	Austria, Germany	À vérifier
RevascularizationThe primary objective of this study is to evaluate the effect of different treatment modalities on clinical outcome of patients suffering from acute lower limb ischemia (ALI). Depending on clinical presentation, anatomical as well as technical considerations, different treatment options are available for revascularisation of affected limbs. Using an observational, international, multicentric study design (min. patient number of 500), the defined primary endpoint of the study, amputation-free survival 90 days after the diagnosis of ALI, will be evaluated.	Myopathies	À vérifier	À vérifier	Austria, Croatia, France, Germany, Hungary, Moldova, Netherlands, Serbia, Switzerland, United Kingdom	À vérifier
Selective CRP apheresis using the PentraSorb®-CRP systemBackground: In patients with acute ST-elevation myocardial infarction (STEMI), the amount of infarcted myocardium (infarct size) is known to be a major predictor for adverse remodeling and recurrent adverse cardiovascular events. Effective cardio-protective strategies with the aim of reducing infarct size are therefore of great interest. Local and systemic inflammation influences the fate of ischemic myocardium and thus, adverse remodeling and clinical outcome. C-reactive protein (CRP) also acts as a potential mechanistic mediator that adversely affects the amount of irreversible myocardial tissue damage after acute myocardial infarction. Objective: The main objectives of the current study are to investigate the efficacy of selective CRP apheresis, using the PentraSorb®-CRP system, as an adjunctive therapy to standard of care for patients with acute STEMI treated with primary PCI. Design: Investigator-initiated, prospective, randomized, open-label (outcome assessors masked), controlled, multicenter, two group trial with a two-stage adaptive design. Innovation: Selective CRP apheresis offers potential to decrease infarct size and consequently improve outcome after PCI for STEMI. This is the first randomized trial investigating the impact of selective CRP apheresis on infarct size in post-STEMI patients. In perspective, the study design allows furthermore to collect robust evidence for the design of a definitive outcome study.	Maladie coronarienne	Non applicable	Immunomodulation	Austria, Germany	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Selective CRP apheresis using the PentraSorb®-CRP system	Maladie coronarienne	Non applicable	NCT04939805	CRP Apheresis in STEMI	RECRUITING
Revascularization	Myopathies	À vérifier	NCT05138679	Evaluation of Acute Lower Limb Ischemia	COMPLETED

Publications

10

Molécule	Indication / population	Titre	Journal	Date
Primary major amputation		Blunt Tibial Injury Is Associated With Primary Amputation for Lower Extremity Vascular Trauma.	The Journal of surgical research
Revascularization		Dengzhanxixin injection for acute ischemic stroke after reperfusion therapy: A double-blind, placebo-controlled, multi-center clinical trial.	IBRO neuroscience reports
Revascularization		Host-state biomarkers and clinical factors for stratification and optimization of cell therapy trials in chronic limb-threatening ischemia: A review.	Regenerative therapy
Revascularization		Long-term safety and effectiveness of hybrid coronary revascularization compared to conventional revascularization strategies: a systematic review and meta-analysis.	Annals of medicine and surgery (2012)
Revascularization		Clinical Impact of Complete Revascularization Before Left Ventricular Assist Device Implantation in Patients With Severe Ischemic Cardiomyopathy.	Artificial organs
Revascularization		Postoperative perfusion volume on territorial arterial spin labeling provides an exploratory risk signal for cerebrovascular autoregulation failure after moyamoya revascularization: a prospective physiological study.	Frontiers in physiology
Revascularization		Acute Myocardial Infarction Secondary to Idiopathic Ascending Aortic Thrombus.	JACC. Case reports
Revascularization		Management of multivessel disease in patients with ST-segment elevation myocardial infarction: questioning routine immediate complete revascularization in all patients.	Coronary artery disease
Primary major amputation		Contemporary Outcomes of Staged Versus Primary Major Amputation for Severe Foot Infection.	Annals of vascular surgery
Primary major amputation		Re: "Contemporary Outcomes of Staged Versus Primary Major Amputation for Severe Foot Infection".	Annals of vascular surgery